Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Female gender-to evaluate effects in the target population for clinical trials.~* History of uterine leiomyoma causing symptoms of bleeding, pressure, or pain, as defined by the American College of Obstetrics and Gynecology (ACOG) practice bulletin:~* Excessive uterine bleeding will be evidenced by either of the following-profuse bleeding with flooding or clots or repetitive periods lasting for more than 8 days; or anemia due to acute or chronic blood loss;~OR~* Pelvic discomfort caused by leiomyomata, either acute and severe or chronic lower abdominal or low back pressure or bladder pressure with urinary frequency not due to urinary tract infection.~* Uterine leiomyoma(ta) of at least 2 cm size.~* In good health. Chronic medication use is acceptable except for glucocorticoid use. Other chronic medication use may be acceptable at the discretion of the research team. Interval use of over-the-counter drugs is acceptable but must be recorded.~* Menstrual cycles of 24 - 35 days.~* Hemoglobin greater than 10 g/dL (for those wishing surgery); iron may be administered to improve red blood cell counts.~* Willing and able to comply with study requirements.~* Age 25 to 50.~* Using mechanical (condoms, diaphragms) sterilization or abstinence methods of contraception for the duration of the study.~* Negative urine pregnancy test.~* Body mass index (BMI) less than or equal to 33, if a surgical candidate or less than or equal to 35, if not a surgical candidate.~* Creatinine less than 1.3 mg/dL.~* Liver function tests within 130% of upper limit.~* If interested in hysterectomy, no desire for fertility.~EXCLUSION CRITERIA:~* Significant abnormalities in the history, physical or laboratory examination.~* Pregnancy.~* Lactation.~* Use of oral, injectable or inhaled glucocorticoids or megestrol within the last year.~* Unexplained vaginal bleeding.~* History of malignancy within the past 5 years.~* Use of estrogen or progesterone-containing compounds, such as oral contraceptives and hormone replacement therapy, within 8 weeks of study entry, including transdermal, injectable, vaginal and oral preparations.~* Use of agents known to induce hepatic P450 enzymes; use of imidazoles.~* Current use of Gonadotropin-releasing hormone (GnRH) analogs or other compounds that affect menstrual cyclicity.~* Follicle stimulating hormone (FSH) greater than 20 IU/mL.~* Untreated cervical dysplasia.~* Need for interval use of narcotics.~* Abnormal adnexal/ovarian mass.~* Use of herbal medication having estrogenic or antiestrogenic effects within the past 3 months.~* Contradiction to anesthesia, for women planning surgery.~* Genetic causes of leiomyomata.~* Previous participation in the study.~* Known recent rapid growth of fibroids, defined as a doubling in size in six months.

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- ulipristal acetate -20 mg (Type: ACTIVE_COMPARATOR): 20 mg daily dose ulipristal acetate for three menstrual cycles or up to 102 days
- ulipristal acetate - 10 mg (Type: ACTIVE_COMPARATOR): 10 mg daily dose ulipristal acetate for three menstrual cycles or up to 102 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo taken daily for three menstrual cycles or up to 102 days
- Pre-ulipristal acetate 10 mg (Type: NO_INTERVENTION): Subjects were studied during one baseline cycle without any intervention before entering ulipristal acetate 10 mg arm
- Pre-ulipristal acetate 20 mg (Type: NO_INTERVENTION): Subjects were studied during one baseline cycle without any intervention before entering ulipristal acetate 20 mg arm
- Pre-placebo (Type: NO_INTERVENTION): Subjects were studied during one baseline cycle without any intervention before entering placebo arm

Based on this trial design, predict the completion outcome and termination type (if applicable).